Targeting sphingosine kinase 1/2 by a novel dual inhibitor SKI-349 suppresses non-small cell lung cancer cell growth

Sphingosine kinase 1 (SphK1) and sphingosine kinase (SphK2) are both important therapeutic targets of non-small cell lung cancer (NSCLC). SKI-349 is a novel, highly efficient and small molecular SphK1/2 dual inhibitor. Here in primary human NSCLC cells and immortalized cell lines, SKI-349 potently i...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Yuhang, Jiang, Kanqiu, Ou, Li, Shen, Mingjing, Yang, Yi, Lu, Jingjing, Xu, Weihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279331/
https://www.ncbi.nlm.nih.gov/pubmed/35831279
http://dx.doi.org/10.1038/s41419-022-05049-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279331/
https://www.ncbi.nlm.nih.gov/pubmed/35831279
http://dx.doi.org/10.1038/s41419-022-05049-4

Ejemplares similares